Feb 21 (Reuters) - Johnson & Johnson JNJ.N:
TREMFYA® (GUSELKUMAB) SUBCUTANEOUS (SC) INDUCTION DATA SUPPORT POTENTIAL TO BE THE FIRST AND ONLY IN ITS CLASS TO OFFER THE OPTION OF BOTH INTRAVENOUS AND SC INDUCTION THERAPY IN ULCERATIVE COLITIS
J&J: STUDY ACHIEVES PRIMARY AND ALL SECONDARY ENDPOINTS AT WEEK 12
J&J: SAFETY DATA FROM ASTRO STUDY WERE CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF TREMFYA
Source text: ID:nPn7jMWf9a
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.